Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people lose roughly 1–2% of their starting body weight per month on Wegovy, though the rate shifts considerably across the treatment timeline. Clinical trial data show an average of around 15% total body-weight reduction over 68 weeks at the 2.4mg maintenance dose — that works out unevenly, with faster losses early on and a slower, steadier phase as the body adjusts. Wegovy (semaglutide) is a prescription-only medicine; a GPhC-registered prescriber must assess whether it is clinically appropriate for you before treatment can begin.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The decision most people arrive at is a simple one: will this work fast enough to be worth it? It's a fair question, and the honest answer is that Wegovy's weight-loss pattern doesn't distribute itself neatly across a calendar. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks. On average, participants lost around 15% of starting body weight. Spread evenly that would be roughly 1% a month, but that isn't how it plays out.
The first four to eight weeks tend to produce the most visible movement. Appetite often falls noticeably as the body acclimatises to semaglutide, and people who pair the medicine with a modest calorie reduction see this reflected on the scales relatively quickly. By months three to six, the rate typically slows. That's not stalling, it's the expected biology. The body recalibrates its energy balance as weight falls, so a smaller monthly drop later in treatment represents genuine, sustained progress rather than the medicine losing effect.
For a practical sense of weekly variation, our breakdown of weekly weight loss on Wegovy works through the same trial data at a finer resolution. If you're focused on the opening weeks specifically, our guide to how much weight you can lose on Wegovy in the first month covers what the evidence suggests before titration is complete. The short version: progress is real, but it rarely arrives in uniform monthly instalments.
Two people on identical doses can lose weight at noticeably different speeds. Starting BMI is probably the biggest variable, someone with a higher BMI typically loses a larger absolute number of kilograms per month early on, even if the percentage is similar. Dose matters too. Wegovy starts at 0.25mg and is titrated by the prescriber over several months toward 2.4mg; the maintenance dose carries most of the effect, so results in months one and two reflect a tolerability phase as much as a therapeutic one.
Diet and activity pattern play a genuine role alongside the medicine. The STEP 1 trial paired semaglutide with structured lifestyle support, and participants who engaged with that element consistently outperformed those who treated the injection as a standalone fix. Sleep quality, stress levels and medication interactions can all influence the picture too. There is a common misconception that Wegovy does the work on its own and lifestyle becomes irrelevant, in practice, the medicine reduces appetite significantly, but what you do with that reduced appetite still shapes the outcome.
If you want a fuller picture of the total weight you might realistically expect over the full course, this page covers the longer-term evidence in detail. For those focused on the early phase, our page on how much you lose on Wegovy in the first month looks at that narrower window in detail.
Once you've thought through realistic expectations, the next practical question is almost always about cost. UK private Wegovy pricing is quoted per pen or per month, and the figures vary between providers by dose and by what's bundled into the headline number. Since Eli Lilly's price adjustments in late 2025, market prices across the private sector have ranged roughly £149–£375 per month depending on dose and provider, those figures are widely reported and should be treated as contextual, not fixed.
What headline prices sometimes omit is worth knowing before you compare: consultation fees, prescription charges, delivery costs and any ongoing clinical support are handled differently across services. Some providers charge for each separately. At nume, one price covers the consultation, the prescription, the medicine, free next-working-day tracked delivery, and seven-day aftercare. We don't position ourselves as the cheapest option available, that's a deliberate choice, because the infrastructure that makes a weight-loss medicine safe to take privately costs something.
The right question for a prescription medicine isn't which service has the lowest number, it's which service includes genuine clinical oversight, verified supply through the licensed UK pharmacy chain, and support if something unexpected happens. For a full breakdown of what Wegovy costs through nume at each dose, our treatment cost page sets this out plainly. Current pricing is confirmed at consultation, where a prescriber also confirms whether Wegovy or another licensed treatment is the better clinical fit for you.
The MHRA has warned repeatedly about counterfeit weight-loss pens sold online, including fake pens containing insulin rather than semaglutide. Enforcement action through 2025 included seizures of around 20 million doses of illegally traded weight-loss medicines, worth approximately £45 million. The common thread in almost every unsafe purchase is price: sellers undercutting the legitimate market by a significant margin, often with no clinical assessment involved.
For a medicine that requires titration, monitoring and prescriber oversight, the cheapest listing is answering the wrong question entirely. Legitimate supply means a pharmacy you can verify on the GPhC register (nume's registration number is 9012878), a real prescriber reviewing your health before every supply, and a supply chain that traces back to Novo Nordisk's authorised UK distributors. Our clinical team reviews every consultation personally, including repeat orders. If you'd like to check whether Wegovy is suitable for you, check your eligibility through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.